协同的多支互动调解了由Chaperone HtrA1有效抑制α-synuclein聚合的有效抑制
bioRxiv : the preprint server for biology
|December 9, 2024
概括
一种催化不活跃的伴侣物,HtrA1*,可以防止α-Syn聚合和扩散在像帕金森氏症这样的神经退行性疾病中. 它使用协同域相互作用来抑制单体和纤维细胞的形成,提供治疗蓝图.
科学领域:
- 神经退行性疾病研究
- 蛋白质的错误折叠和聚合.
- 查帕龙蛋白的功能是指陪伴蛋白.
背景情况:
- 阿尔法同核素 (α-Syn) 错误折叠和聚合是帕金森病 (PD) 和其他同核素病变的核心原因.
- 这些聚合物以类似子的方式传播,推动疾病的进展.
- 了解抑制α-Syn聚合的陪伴机制是治疗开发的关键.
研究的目的:
- 为了研究一种催化不活跃的伴侣物,HtrA1*,如何抑制α-Syn聚合和模板播种.
- 阐明HtrA1*对α-Syn.抑制作用背后的分子机制.
主要方法:
- 生物分子NMR光谱学
- 原子力显微镜 (AFM) 的应用
- 基于罗塞塔的计算分析.
- 聚合动力学测定试验
主要成果:
- HtrA1*有效地抑制了α-Syn单体聚合和纤维细胞播种.
- 在HtrA1*的PDZ和蛋白酶域与α-Syn之间的协同相互作用至关重要.
- 该PDZ域绑定α-Syn单体C端和纤维细胞失序区域; 蛋白酶域在T92/A93.3切割NAC域.
结论:
- 通过多端相互作用,HtrA1*作为α-Syn聚合和播种的强有力的抑制剂.
- 这项研究揭示了一种通过沙佩龙介导的α-Syn.抑制的高分辨率机制.
- 这种HtrA1抑制机制为开发针对蛋白质聚合疾病的新疗法提供了蓝图.
相关概念视频
Molecular Chaperones and Protein Folding
17.7K
The native conformation of a protein is formed by interactions between the side chains of its constituent amino acids. When the amino acids cannot form these interactions, the protein cannot fold by itself and needs chaperones. Notably, chaperones do not relay any additional information required for the folding of polypeptides; the native conformation of a protein is determined solely by its amino acid sequence. Chaperones catalyze protein folding without being a part of the folded protein.
The...
The...
17.7K
Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.7K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.7K
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Drugs Affecting Neurotransmitter Release or Uptake
947
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
947
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
618
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
618
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
520
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
520


